Patents by Inventor Ming Fai Chan
Ming Fai Chan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11931282Abstract: The present disclosure provides a bracewear for spinal correction and a system for posture training. The system for posture training involves both active and passive corrective forces by using the bracewear and a biofeedback system to address the spinal correction, which can eliminate the adversity of conventional hard braces and reduce the psychological and physiological barriers to treatment.Type: GrantFiled: October 15, 2020Date of Patent: March 19, 2024Assignee: The Hong Kong Polytechnic UniversityInventors: Yiu-Wan Joanne Yip, Yin Ling Sit, Ting Hin Mak, Kit Lun Yick, Tsz Hei Cheung, Sui Pui Ng, Kenny Yat Hong Kwan, Mei Chun Cheung, Ming Fai Chan
-
Publication number: 20220117769Abstract: The present disclosure provides a bracewear for spinal correction and a system for posture training. The system for posture training involves both active and passive corrective forces by using the bracewear and a biofeedback system to address the spinal correction, which can eliminate the adversity of conventional hard braces and reduce the psychological and physiological barriers to treatment.Type: ApplicationFiled: October 15, 2020Publication date: April 21, 2022Inventors: Yiu-Wan Joanne YIP, Yin Ling SIT, Ting Hin MAK, Kit Lun YICK, Tsz Hei CHEUNG, Sui Pui NG, Kenny Yat Hong KWAN, Mei Chun CHEUNG, Ming Fai CHAN
-
Patent number: 7605144Abstract: This invention provides novel compounds selected from the group consisting of a 1,5-substituted pyrimidine derivative or analog and substituted furano-pyrimidone analogs. The compounds are useful to treat or prevent diseases such as cancer.Type: GrantFiled: October 7, 2003Date of Patent: October 20, 2009Assignee: Celmed Oncology (USA), Inc.Inventors: H. Michael Shepard, Ming Fai Chan, Michael P. Groziak
-
Publication number: 20040077588Abstract: This invention provides novel substrate compounds that selectively inhibit the proliferation f path logical cells, for example, pathological cells that endogenously overexpress a target enzyme that confers resistance to biologic and chemotherapeutic agents. The enzyme acts on a substrate compound to 1) convert it to a cellular toxin and/or 2) release a toxic byproduct. In one embodiment, the activity of the target enzyme has been greatly enhanced in a target cell as a result of loss f tum r suppressor function and/or selection resulting from previous exposure to chemotherapy. In another embodiment, the pathological cell contains a target enzyme that is an expression product of an infectious agent in the cell. Further provided by this invention is a method for treating a subject by delivering to the subject a prodrug as described herein. The prodrugs f this invention may be used alone or in combination with ther chemotherapeutics or alternative anti-cancer therapies such as radiation.Type: ApplicationFiled: October 7, 2003Publication date: April 22, 2004Inventors: H. Michael Shepard, Ming Fai Chan, Michael P. Groziak
-
Patent number: 6683061Abstract: This invention provides novel substrate compounds that selectively inhibit the proliferation of pathological cells, for example, pathological calls that endogenously overexpress a target enzyme that confers resistance to biologic and chemotherapeutic agents. The enzyme acts on a substrate compound to 1) convert it to a cellular toxin and/or 2) release a toxic byproduct. In one embodiment, the activity of the target enzyme has been greatly enhanced in a target cell as a result of loss of tumor suppressor function and/or selection resulting from previous exposure to chemotherapy. In another embodiment, the pathological cell contains a target enzyme that is an expression product of an infectious agent in the cell. Further provided by this invention is a method for treating a subject by delivering to the subject a prodrug as described herein. The prodrugs of this invention may be used alone or in combination with other chemotherapeutics or alternative anti-cancer therapies such as radiation.Type: GrantFiled: October 10, 2001Date of Patent: January 27, 2004Assignee: NewBiotics, Inc.Inventors: H. Michael Shepard, Ming Fai Chan, Michael P. Groziak
-
Patent number: 6613804Abstract: Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: GrantFiled: December 4, 2001Date of Patent: September 2, 2003Assignee: Encysive Pharmaceuticals, Inc.Inventors: Ming Fai Chan, Timothy Kogan, Erik Joel Verner, Adam Kois, Vitukudi Narayanaiyengar Balaji
-
Patent number: 6541498Abstract: N-(5-isoxazolyl)benzenesulfonamides and N-(3-isoxazolyl)benzenesulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(5-isoxazolyl)biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. N-isoxzolyl-4-biphenylsulfonamides are particularly preferred. These compounds exhibit activity as endothelin receptor B antagonists. Methods for treating endothelin-mediated disorders, particularly inflammatory diseases, such as asthma, by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: GrantFiled: December 27, 2000Date of Patent: April 1, 2003Assignee: Texas BiotechnologyInventors: Ming Fai Chan, Bore Gowda Raju, Adam Kois, Erik Joel Verner, Chengde Wu, Rosario Silvestre Castillo, Venkatachalapathi Yalamoori, Vitukudi Narayanaiyengar Balaji, Kalyanaraman Ramnarayan
-
Publication number: 20020115642Abstract: The present invention provides compositions comprising improved beta-lactam antibiotics and methods for applying these compositions to inhibit the growth of microbial infections. The improved antibiotics are capable of inhibiting the growth of both antibiotic sensitive and antibiotic resistant microorganisms In addition, the invention provides methods for treating a subject infected with a microorganism by administering the compositions of the invention.Type: ApplicationFiled: May 1, 2001Publication date: August 22, 2002Inventors: Ming Fai Chan, Rosario S. Castillo, Qing Li, Venkata Ramana Doppalapudi, Mark Stephen Hixon, Thomas J. Lobl
-
Publication number: 20020095041Abstract: Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: ApplicationFiled: December 4, 2001Publication date: July 18, 2002Inventors: Ming Fai Chan, Timothy Kogan, Erik Joel Verner, Adam Kois, Vitukudi Narayanaiyengar Balaji
-
Patent number: 6384261Abstract: Phosphoramidates and phosphinic amides and related compounds are provided. Also provided are methods that use the compounds for modulating the activity of the endothelin family of peptides are provided. In particular, compounds having formula: in which A, B, R1 and R2 are as described are provided. Also provided are methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these compounds or prodrugs thereof. Methods for elucidating the physiological and pathophysiological roles of endothelin, as well as isolating endothelin receptors are also provided.Type: GrantFiled: September 3, 1998Date of Patent: May 7, 2002Assignee: Texas Biotechnology CorporationInventors: Ming Fai Chan, Erik Joel Verner
-
Patent number: 6376523Abstract: N-(5-isoxazolyl)benzenesulfonamides and N-(3-isoxazolyl)benzenesulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(5-isoxazolyl)biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. N-isoxzolyl-4-biphenylsulfonamides are particularly preferred. These compounds exhibit activity as endothelin receptor B antagonists. Methods for treating endothelin-mediated disorders, particularly inflammatory diseases, such as asthma, by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: GrantFiled: November 12, 1999Date of Patent: April 23, 2002Assignee: Texas Biotechnology CorporationInventors: Ming Fai Chan, Bore Gowda Raju, Adam Kois, Erik Joel Verner, Chengde Wu, Rosario Silvestre Castillo, Venkatachalapathi Yalamoori, Vitukudi Narayanaiyengar Balaji
-
Patent number: 6342610Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: GrantFiled: November 7, 1997Date of Patent: January 29, 2002Assignee: Texas Biotechnology Corp.Inventors: Ming Fai Chan, Chengde Wu, Bore Gowda Raju, Timothy Kogan, Erik Joel Verner, Rosario Silvestre Castillo, Venkatachalapathi Yalamoori, Adam Kois, Vitukudi Narayanaiyengar Balaji
-
Patent number: 6331637Abstract: N-alkyl, N-alkenyl, N-alkynyl, N-aryl and N-fused bicyclo or tricyclo thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, (phenyl) and (phenoxy)thienylsulfonamides, (phenyl) and (phenoxy)furylsulfonamides, and (phenyl) and (phenoxy)pyrrolylsulfonamides and methods of using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: GrantFiled: March 22, 1999Date of Patent: December 18, 2001Assignee: Texas Biotechnology CorporationInventors: Ming Fai Chan, Chengde Wu, Bore Gowda Raju, Timothy Kogan, Adam Kois, Erik Joel Verner, Rosario Silvestre Castillo, Venkatachalapathi Yalamoori, Vitukudi Narayanaiyengar Balaji
-
Publication number: 20010036958Abstract: N-(5-isoxazolyl)benzenesulfonamides and N-(3-isoxazolyl)benzenesulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(5-isoxazolyl)biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. N-isoxzolyl-4-biphenylsulfonamides are particularly preferred. These compounds exhibit activity as endothelin receptor B antagonists. Methods for treating endothelin-mediated disorders, particularly inflammatory diseases, such as asthma, by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: ApplicationFiled: December 27, 2000Publication date: November 1, 2001Inventors: Ming Fai Chan, Bore Gowda Raju, Adam Kois, Erik Joel Verner, Chengde Wu, Rosario Silvestre Castillo, Venkatachalapathi Yalamoori, Vitukudi Narayanaiyengar Balaji, Kalyanaraman Ramnarayan
-
Publication number: 20010021714Abstract: Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)-furylsulfonamides and N-(isoxazolyl)pyrrolyisulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prod rugs thereof that inhibit or increase the activity of endothelin are also provided.Type: ApplicationFiled: November 7, 1997Publication date: September 13, 2001Inventors: MING FAI CHAN, CHENGDE WU, BORE GOWDA RAJU, TIMOTHY KOGAN, ERIK JOEL VERNER, ROSARIO SILVESTRE CASTILLO, VENKATACHALAPATHI YALAMOORI, ADAM KOIS, VITUKUDI NARAYANAIYENGAR BALAJI
-
Publication number: 20010014694Abstract: Methods, compositions, and compounds for modulating the activity of an endothelin peptide are provided.Type: ApplicationFiled: March 14, 2001Publication date: August 16, 2001Inventors: Ming Fai Chan, Vitukudi Narayanaiyengar Balaji, Rosario Silvestre Castillo, Adam Kois, Bore Gowda Raju, Chengde Wu
-
Patent number: 6265428Abstract: Methods, compositions, and compounds for modulating the activity of an endothelin peptide are provided. The methods use compositions that contain compounds of formula (1): where X and Y are selected from groups that include O, S, and NH; and Ar1, Ar2 and Ar3 are independently selected from substituted or unsubstituted groups that include 5 to 6 membered aryl groups and heteroaryl groups that contain one or two heteroatom(s). The methods are effected by contacting endothelin receptors with one or more of the compounds or with compositions containing one or more of the compounds prior to, simultaneously with, or subsequent to contacting the receptors with an endothelin peptide.Type: GrantFiled: June 8, 1999Date of Patent: July 24, 2001Assignee: Texas Biotechnology CorporationInventors: Ming Fai Chan, Vitukudi Narayanaiyengar Balaji, Rosario Silvestre Castillo, Adam Kois, Bore Gowda Raju, Chengde Wu
-
Patent number: 6254001Abstract: A method of transferring business card information from a first user to a second user includes the steps of providing said first and second users with an electronic business card device, storing data similar to that stored on a business card in a memory in each of the electronic business cards, selectively displaying at least some of the stored business card data on a visual display screen, and selectively transferring the stored business card data of at least the first user to the electronic business card of the other user for storage and selective retrieval.Type: GrantFiled: February 22, 1999Date of Patent: July 3, 2001Inventor: George Ming Fai Chan
-
Patent number: 6030991Abstract: N-(5-isoxazolyl)benzenesulfonamides and N-(3-isoxazolyl) benzene-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(5-isoxazolyl)-biphenylsulfonamides and N-(3-isoxazolyl)biphenylsulfonamides and methods for inhibiting the binding of an endothelin peptide to an endothelin receptor or increasing the activity of endothelin peptides by contacting the receptor with a sulfonamide are provided. N-isoxzolyl-4-biphenylsulfonamides are particularly preferred. These compounds exhibit activity as endothelin receptor B antagonists. Methods for treating endothelin-mediated disorders, particularly inflammatory diseases, such as asthma, by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.Type: GrantFiled: December 6, 1996Date of Patent: February 29, 2000Assignee: Texas Biotechnology Corp.Inventors: Ming Fai Chan, Bore Gowda Raju, Adam Kois, Erik Joel Verner, Chengde Wu, Rosario Silvestre Castillo, Venkatachalapathi Yalamoori, Vitukudi Narayanaiyengar Balaji
-
Patent number: D553038Type: GrantFiled: January 19, 2006Date of Patent: October 16, 2007Assignee: Royal Consumer Information Products, Inc.Inventors: Robert J. Robinson, George Ming Fai Chan